Focused On-demand Library for U4/U6 small nuclear ribonucleoprotein Prp3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O43395

UPID:

PRPF3_HUMAN

Alternative names:

Pre-mRNA-splicing factor 3; U4/U6 snRNP 90 kDa protein

Alternative UPACC:

O43395; B4DSY9; O43446; Q5VT54

Background:

The U4/U6 small nuclear ribonucleoprotein Prp3, also known as Pre-mRNA-splicing factor 3 and U4/U6 snRNP 90 kDa protein, is pivotal in pre-mRNA splicing. It functions as a component of the U4/U6-U5 tri-snRNP complex, playing a crucial role in spliceosome assembly and the formation of the precatalytic spliceosome (spliceosome B complex).

Therapeutic significance:

Retinitis pigmentosa 18, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field, is linked to mutations affecting the gene encoding U4/U6 small nuclear ribonucleoprotein Prp3. Understanding the role of this protein could open doors to potential therapeutic strategies for this condition.